MBX Biosciences Initiates Phase 3 Trial for Hypoparathyroidism Treatment

MBX Biosciences, Inc. has begun its pivotal Phase 3 oPTimize trial, administering the first patient dose of once-weekly canvuparatide for adults with hypoparathyroidism. This trial will assess the treatment's efficacy and safety, with secondary goals including normalizing urinary calcium excretion and improving physical function, marking a key step in its development.